Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (8401)	5/19/2003 8:47:54 PM
From: Ian@SI	Read Replies (1) \| Respond to of 52153

Anyone know what PDLI's royalty on Avastatin is? According to Briefing.Com, it's 3%. * 07:17 ET Genentech announces positive Avastin study results (DNA) 37.90: Co announces that a Phase III study of Avastin plus chemotherapy in previously-untreated metastatic colorectal cancer patients met its primary endpoint of improving overall survival. According to the co, the magnitude of the benefit observed far exceeded what the study was designed to demonstrate. The trial also met the secondary endpoints of progression-free survival, response rate, and duration of response. Avastin is considered a key drug for DNA with a sales potential of over $1 bln. Of note,<font size=5> PDLI is set to receive a 3% royalty on worldwide sales.